Evidence map›Paper›PMID 37193080›Full record

ArticleBioImpacts : BI2023

Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin.

Samira Gholizadeh, Hossein Haghaei, Hosna Karami, Somaieh Soltani, Mostafa Zakariazadeh, Javad Shokri

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioImpacts : BI, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Samira GholizadehPharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0001-6705-1150
Hossein HaghaeiFaculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Hosna KaramiPharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Somaieh SoltaniPharmacy Faculty, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-0102-2960
Mostafa ZakariazadehDepartement of Biology, Faculty of Sciences, Payame Noor University, PO.box 19395-3697, Tehran, Iran.
Javad ShokriPharmacy Faculty, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IRPayame Noor University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FingolimodHuman serum albuminLipid-like drugMolecular modelingpH-dependent solubilitySpectroscopic Techniques

Identifiers

PMID37193080
PMCPMC10182447
OpenAlexW4321384572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.